Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study

被引：0

作者：

Platzbecker, U. ^{[1
]}

Della Porta, M. G. ^{[2
,3
]}

Santini, V. ^{[4
]}

Zeidan, A. M. ^{[5
,6
]}

Fenaux, P. ^{[7
]}

Komrokji, R. S. ^{[8
]}

Shortt, J. ^{[9
,10
]}

Valcarcel, D. ^{[11
]}

Jonasova, A. ^{[12
]}

Dimicoli-Salazar, S. ^{[13
]}

Tiong, I. S. ^{[14
]}

Lin, C. -C. ^{[15
]}

Li, J. ^{[16
]}

Zhang, J. ^{[16
]}

Giuseppi, A. C. ^{[16
]}

Kreitz, S. ^{[17
]}

Pozharskaya, V. ^{[16
]}

Keeperman, K. L. ^{[16
]}

Rose, S. ^{[16
]}

Shetty, J. K. ^{[17
]}

Hayati, S. ^{[16
]}

Vodala, S. ^{[16
]}

Degulys, A. ^{[18
,19
]}

Paolini, S. ^{[20
]}

Cluzeau, T. ^{[21
]}

Garcia-Manero, G. ^{[22
]}

机构：

[1] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[2] IRCCS Humanitas Res Hosp, Ctr Canc, Milan, Italy

[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[4] Univ Florence, MDS Unit, AOUC, Hematol, Florence, Italy

[5] Yale Univ, Yale Sch Med, New Haven, CT USA

[6] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[7] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France

[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[9] Monash Univ, Melbourne, Vic, Australia

[10] Monash Hlth, Melbourne, Vic, Australia

[11] Hosp Univ Vall dHebron, Barcelona, Spain

[12] Charles Univ Prague, Gen Univ Hosp, Dept Med Hematol, Prague, Czech Republic

[13] Hop Haut Leveque, Ctr Hosp Univ Bordeaux, Bordeaux, France

[14] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Vic, Australia

[15] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Celgene Int Sarl, Boudry, Switzerland

[18] Vilnius Univ Hosp Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[19] Vilnius Univ, Inst Clin Med, Fac Med, Vilnius, Lithuania

[20] IRCCS Univ Hosp Bologna, Seragnoli Inst Hematol, Bologna, Italy

[21] Univ Cote dAzur, CHU Nice, Dept Hematol Clin, Nice, France

[22] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V61

引用

页码：16 / 17

页数：2

共 35 条

[21] Multiple periods of transfusion independence (TI) with luspatercept (LUSP) treatment (Tx) and the impact of dose escalation in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) from the MEDALIST study
Platzbecker, U.
Santini, V
Komrokji, R. S.
Zeidan, A. M.
Garcia-Manero, G.
Buckstein, R. J.
Oliva, E. N.
Pozharskaya, V
Nadal, J. A.
Miteva, D.
Fenaux, P.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 18 - 19
[22] Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial
Zeidan, Amer M.
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Santini, Valeria
Garcia-Manero, Guillermo
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Rose, Shelonitda
Lai, Yinzhi
Valcarcel, David
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S387 - S388
[23] Luspatercept versus epoetin alfa in erythropoiesisstimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Porta, Matteo Giovanni Della
Garcia-Manero, Guillermo
Santini, Valeria
Zeidan, Amer M.
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Pilot, Richard
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Lai, Yinzhi
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Fenaux, Pierre
Platzbecker, Uwe
LANCET HAEMATOLOGY, 2024, 11 (09): : e646 - e658
[24] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
Komrokji, Rami S.
Santini, Valeria
Fenaux, Pierre
Savona, Michael R.
Madanat, Yazan F.
Berry, Tymara
Sherman, Laurie
Navada, Shyamala
Feller, Faye M.
Sun, Libo
Xia, Qi
Wan, Ying
Huang, Fei
Zeidan, Amer M.
Platzbecker, Uwe
BLOOD, 2023, 142
[25] Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
Oliva, Esther Natalie
Platzbecker, Uwe
Porta, Matteo Giovanni Della
Garcia-Manero, Guillermo
Santini, Ualeria
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
Pelligra, Christopher G.
Guo, Shien
Yucel, Aylin
Glassberg, Mrudula B.
Eliason, Laurie
Hnoosh, Ahmed
Miteva, Dimana
Rose, Shelo
Santiri, Valeria
Kreitz, Sandra
Sekeres, Mikkael A.
Zeidan, Amer M.
BLOOD, 2024, 144 : 3217 - 3218
[26] Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
Mukherjee, Sudipto
Savill, Kristin M.
Gajra, Ajeet
Gentile, Danielle
Falkenstein, Angelica
Miller, Talia
Laney, JaLyna
McBride, Ali
BLOOD, 2022, 140 : 10998 - 11000
[27] Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
Mittelman, Moshe
Henry, David H.
Glaspy, John
Tombak, Anil
Harrup, Rosemary Anne
Madry, Krzysztof
Grabowska, Barbara
Platzbecker, Uwe
Lee, Tyson
Modelska, Katharina
BLOOD, 2023, 142
[28] Luspatercept in patients with low-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS): long-term efficacy and safety data from the phase 3 MEDALIST study
Platzbecker, U.
Santini, V
Komrokji, R. S.
Zeidan, A.
Garcia-Manero, G.
Buckstein, R.
Miteva, D.
Keeperman, K.
Holot, N.
Zhang, J.
Nadal, J. A.
Rosettani, B.
Yucel, A.
Fenaux, P.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 134 - 134
[29] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
Zeidan, Amer Methqal
Platzbecker, Uwe
Santini, Valeria
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Diez-Campelo, Maria
Valcarcel, David
Illmer, Thomas
Jonasova, Anna
Belohlavkova, Petra
Sherman, Laurie Jill
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Sun, Libo
Wan, Ying
Huang, Fei
Komrokji, Rami S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
Platzbecker, Uwe
Komrokji, Rami S.
Zeidan, Amer M.
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Jonasova, Anna
Illmer, Thomas
Sherman, Laurie
Berry, Tymara
Riggs, Jennifer
Xia, Qi
Navada, Shyamala
Wan, Ying
Huang, Fei
Feller, Faye M.
Santini, Valeria
BLOOD, 2023, 142

← 1 2 3 4 →